Li Y, Zhang Y, Li X, Yi S, Xu J. Achieve-of-function mutations: an rising benefit for most cancers biology. Traits Biochem Sci. 2019;44:659–74.
Chen S, Zhao Y, Liu S, Zhang J, Assaraf YG, Cui W, et al. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. Drug Resist Updat. 2022;61:100821.
Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in most cancers. Sign Transduct Goal Ther. 2021;6:386.
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Evaluation of resistance mechanisms and medical implications in sufferers with egfr t790m-positive lung most cancers and bought resistance to osimertinib. JAMA Oncol. 2018;4:1527–34.
Terakawa J, Serna VA, Taketo MM, Daikoku T, Suarez AA, Kurita T. Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K actions. Proc Natl Acad Sci USA. 2019;116:4528–37.
Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, et al. Aurora A kinase inhibition is artificial deadly with lack of the RB1 tumor suppressor gene. Most cancers Discov. 2019;9:248–63.
Lord CJ, Tutt AN, Ashworth A. Artificial lethality and most cancers remedy: classes discovered from the event of PARP inhibitors. Annu Rev Med. 2015;66:455–70.
Menezes DL, Holt J, Tang Y, Feng J, Barsanti P, Pan Y, et al. An artificial deadly display screen reveals enhanced sensitivity to ATR inhibitor therapy in mantle cell lymphoma with ATM loss-of-function. Mol Most cancers Res. 2015;13:120–9.
Mittal V. EpitheliaL mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395–412.
Shoaib M, Sorensen CS. Epigenetic deficiencies and replicative stress: driving most cancers cells to an early grave. Most cancers Cell. 2015;28:545–7.
Peyraud F, Italiano A. Mixed PARP inhibition and immune checkpoint remedy in strong tumors. Cancers. 2020;12:1502.
Ding N, Maiuri AR, O’Hagan HM. The rising position of epigenetic modifiers in restore of DNA harm related to persistent inflammatory ailments. Mutat Res Rev Mutat Res. 2019;780:69–81.
Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Artificial lethality by focusing on EZH2 methyltransferase exercise in ARID1A-mutated cancers. Nat Med. 2015;21:231–8.
Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang Okay, et al. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor development. Most cancers Lett. 2015;359:198–205.
Kalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, et al. MAT2A inhibition blocks the expansion of MTAP-deleted most cancers cells by decreasing PRMT5-dependent mRNA splicing and inducing DNA harm. Most cancers Cell. 2021;39:209–24.
Kausar S, Abbas MN, Cui H. A overview on the DNA methyltransferase household of bugs: facet and prospects. Int J Biol Macromol. 2021;186:289–302.
Zhang W, Xu J. DNA methyltransferases and their roles in tumorigenesis. Biomark Res. 2017;5:1.
Pollyea DA, Pratz Okay, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in sufferers with newly identified acute myeloid leukemia: long run follow-up from a section 1b research. Am J Hematol. 2021;96:208–17.
Liu YC, Kwon J, Fabiani E, Xiao Z, Liu YV, Follo MY, et al. Demethylation and up-regulation of an oncogene after hypomethylating remedy. N Engl J Med. 2022;386:1998–2010.
Zhu Y, Xia T, Chen DQ, Xiong X, Shi L, Zuo Y, et al. Promising position of protein arginine methyltransferases in overcoming anti-cancer drug resistance. Drug Resist Updat. 2024;72:101016.
Alsulami AF, Torres PHM, Moghul I, Arif SM, Chaplin AK, Vedithi SC, et al. COSMIC most cancers gene census 3D database: understanding the impacts of mutations on most cancers targets. Temporary Bioinform. 2021;22:bbab220.
Russler-Germain DA, Spencer DH, Younger MA, Lamprecht TL, Miller CA, et al. The R882H DNMT3A mutation related to AML dominantly inhibits wild-type DNMT3A by blocking its capacity to type energetic tetramers. Most cancers Cell. 2014;25:442–54.
Buettner R, Yim SO, Hong YS, Boncinelli E, Tainsky MA. Alteration of homeobox gene expression by N-ras transformation of PA-1 human teratocarcinoma cells. Mol Cell Biol. 1991;11:3573–83.
Santini V. Novel therapeutic methods: hypomethylating brokers and past. Hematology Am Soc Hematol Educ Program. 2012;2012:65–73.
Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak M, Fu D, et al. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor development. Proc Natl Acad Sci USA. 2011;108:18061–6.
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424–33.
Ishiguro Okay, Kitajima H, Niinuma T, Maruyama R, Nishiyama N, Ohtani H, et al. Twin EZH2 and G9a inhibition suppresses a number of myeloma cell proliferation by regulating the interferon sign and IRF4-MYC axis. Cell Dying Discov. 2021;7:7.
San José-Enériz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, et al. Discovery of first-in-class reversible twin small molecule inhibitors in opposition to G9aand DNMTs in hematological malignancies. Nat Commun. 2017;8:15424.
Moufarrij S, Srivastava A, Gomez S, Hadley M, Palmer E, Austin PT, et al. Combining DNMT and HDAC6 inhibitors will increase anti-tumor immune signaling and reduces tumor burden in ovarian most cancers. Sci Rep. 2020;10:3470.
Choi HJ, Park JH, Park M, Gained HY, Joo HS, Lee CH. et al.UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1.EMBO Rep.2015;16:1288–89.
Ebeid Okay, Meng X, Thiel KW, Do AV, Geary SM, Morris AS, et al. Synthetically deadly nanoparticles for therapy of endometrial most cancers. Nat Nanotechnol. 2018;13:72–81.
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–53.
Qin Y, Zhu W, Xu W, Zhang B, Shi S, Ji S, et al. LSD1 sustains pancreatic most cancers development through sustaining HIF1alpha-dependent glycolytic course of. Most cancers Lett. 2014;347:225–32.
Lv S, Zhao X, Zhang E, Yan Y, Ma X, Li N, et al. Lysine demethylase KDM1A promotes cell development through FKBP8-BCL2 axis in hepatocellular carcinoma. J Biol Chem. 2022;298:102374.
Li N, Yang L, Zuo H. Arborinine suppresses ovarian most cancers growth by inhibition of LSD1. J]. Life Sci. 2022;291:120275.
Ismail T, Lee HK, Kim C, Kwon T, Park TJ, Lee HS. KDM1A microenvironment, its oncogenic potential, and therapeutic significance. Epigenet Chromatin. 2018;11:33.
Tao DL, Tassi Yunga S, Williams CD, McCarty OJT. Aspirin and antiplatelet therapies in most cancers. Blood. 2021;137:3201–11.
